BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Connext Completes Phase 1 for CNT201, Eyes Phase 2 Launch and Expansion into Peyronie’s Disease

Conducted under U.S. FDA-cleared IND– Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease Connext, a clinical s...

May 09, 2025 | News

Aroa Biosurgery Surpasses 100 Peer-Reviewed Studies Validating AROA ECM Technology in Wound Care

Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence. There are now over 100 peer-reviewed stud...

May 05, 2025 | Report

Genmab to Submit sBLA for Epcoritamab-R2 Combination in Relapsed/Refractory Follicular Lymphoma Following Positive Phase 3 Data

--Genmab A/S (Nasdaq: GMAB) announced its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to t...

May 05, 2025 | Regulatory

Innovent Biologics Secures NMPA Approval for Limertinib as First-Line Therapy for EGFR-Mutated NSCLC in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

April 28, 2025 | News

Oligonucleotide Market Surges as RNA-Based Therapeutics and CDMO Investments Redefine Global Healthcare Strategies

The global oligonucleotide market, once considered niche, has emerged as a pivotal segment in advanced therapeutics and innovative manufacturing strategies...

April 24, 2025 | Analysis

Why Cell Therapy Systems Are Going Automatic: A New Era of Manufacturing

Cell therapy stands at the forefront of modern medicine, offering transformative potential for treating a wide spectrum of diseas...

April 22, 2025 | Report

XellSmart Receives IND Approval from FDA for iPSC-Derived Cell Therapy in Parkinson’s Disease

In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submi...

April 16, 2025 | News

Telix Reports Positive Preliminary Results from IPAX-Linz Study of TLX101 in Recurrent High-Grade Glioma

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101&nb...

April 16, 2025 | News

Patent Wars and Patient Lives: Inside Roche vs Natco Over Risdiplam

In a courtroom packed with legal heavyweights, global pharmaceutical giant F. Hoffmann-La Roche AG faced off against Indian generic manufac...

April 14, 2025 | Analysis

RemeGen’s Telitacicept Shows Best-in-Class Efficacy in Phase 3 Trial for Generalized Myasthenia Gravis

On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept...

April 09, 2025 | News

NUS Researchers Harness AI and 3D Bioprinting to Personalise Gum Tissue Grafts

AI-enabled workflow streamlines oral soft tissue fabrication, paving the way for personalised, less invasive dental treatments A team of researchers from ...

April 07, 2025 | News

Senhwa’s CX-4945 Shows Promising Disease Control and Durability in Refractory Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...

April 03, 2025 | News

Ascletis’ ASC30 SQ Injection Shows 36-Day Half-Life in Phase Ib Obesity Trial

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supp...

April 01, 2025 | News

Vaximm Reports Promising Final Data from Phase 2a Trial of Oral Vaccine VXM01 with Avelumab in Recurrent Glioblastoma

Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, announced fina...

March 27, 2025 | News

Stay Connected